Varanasi News Magazine

30+ Active Companies working to develop 30+ Pipeline Therapies for PARP Inhibitors Treatment Landscape | Major Companies – AstraZeneca, Eisai Co., BeiGene, Ribon Therapeutics, and Others.

 Breaking News
  • No posts were found

30+ Active Companies working to develop 30+ Pipeline Therapies for PARP Inhibitors Treatment Landscape | Major Companies – AstraZeneca, Eisai Co., BeiGene, Ribon Therapeutics, and Others.

April 12
17:40 2023
30+ Active Companies working to develop 30+ Pipeline Therapies for PARP Inhibitors Treatment Landscape | Major Companies - AstraZeneca, Eisai Co., BeiGene, Ribon Therapeutics, and Others.

DelveInsight’s, “PARP Inhibitors Pipeline Insights 2023,” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in PARP Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

In the PARP Inhibitors pipeline report, a detailed description of the drug is given which includes the mechanism of action of the drug, PARP Inhibitors clinical trials studies, PARP Inhibitors NDA approvals (if any), and product development activities comprising the technology, PARP Inhibitors collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

 

Key takeaways from the PARP Inhibitors Pipeline Report

 

  • DelveInsight’s PARP Inhibitors pipeline report depicts a robust space with 30+ active players working to develop 30+ pipeline therapies for PARP Inhibitors treatment.

 

  • The leading PARP Inhibitors Companies include TESARO, AstraZeneca, Sun BioPharma, Eisai Co, BeiGene,  IMPACT Therapeutics, Ribon Therapeutics, Pfizer, Medivation Inc, AbbVie, Merck Sharp & Dohme LLC, Bristol-Myers Squibb, and others

 

  • Promising PARP Inhibitors Pipeline Therapies include Talazoparib, Veliparib, carboplatin, Paclitaxel, Olaparib, Rucaparib, Nivolumab, Abiraterone, and others.

 

  • PARP Inhibitors companies and academics are working to assess challenges and seek opportunities that could influence PARP Inhibitors R&D. The PARP Inhibitors pipeline therapies under development are focused on novel approaches to treat/improve PARP Inhibitors.

 

To explore more information on the latest breakthroughs in the PARP Inhibitors Pipeline treatment landscape of the report, click here @ PARP Inhibitors Pipeline Outlook

 

PARP Inhibitors Overview

PARP is a family of proteins loosely based on structural similarity and function. PARP proteins are composed of two ribose moieties and two phosphates per unit polymer. PARP1 and PARP2 are enzymes involved in a DNA repair pathway for SSBs called BER. The best-known PARP is PARP1. This enzyme was first reported in 1963.

 

Recent Developmental Activities in the PARP Inhibitors Treatment Landscape

 

  • July 2020: Oncology Venture announced that it has secured the remaining ownership in its priority PARP inhibitor (2X-121) program along with its 2X-111 program, by acquiring all outstanding shares in Oncology Venture US Inc. (formerly 2X Oncology, Inc.) from its external shareholders and warrantholders. As a result of the transaction, the Company now has 100 % ownership of 2X-121, which is being clinically developed as an anti-cancer therapeutic, as well as being tested as an anti-viral agent against COVID-19. Similarly, the Company now has 100% ownership of 2X-111, which is being clinically developed as an anti-cancer therapeutic via a recently announced license agreement with Smerud Medical Research International.

 

PARP Inhibitors Emerging Drugs

 

  • Pamiparib: BeiGene

Pamiparib (BGB-290) is an investigational small molecule inhibitor of PARP1 and PARP2. Pamiparib is being evaluated as a monotherapy in pivotal clinical trials in China in recurrent platinum-sensitive and BRCA1/2 mutated ovarian cancers. It is currently in global clinical development as a monotherapy, and in combination with other agents, including BeiGene’s investigational anti-PD1 antibody, tislelizumab (BGB-A317), for a variety of solid tumor malignancies.

 

Request a sample and discover the recent advances in PARP Inhibitors Ongoing Clinical Trial Analysis and Medications, click here @ PARP Inhibitors Treatment Landscape

 

PARP Inhibitors Pipeline Segmentation: Phases

  • Late-stage products (Phase III and
  • Mid-stage products (Phase II and
  • Early-stage products (Phase I/II and Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates

 

PARP Inhibitors Pipeline: Route of Administration

  • Infusion
  • Intradermal
  • Intramuscular
  • Intranasal
  • Intravaginal
  • Oral
  • Parenteral
  • Subcutaneous
  • Topical.

 

PARP Inhibitors Pipeline Therapeutics Assessment

There are approx. 30+ key companies which are developing the PARP Inhibitors. The companies which have their PARP Inhibitors drug candidates in the most advanced stage, i.e. phase III include, BeiGene.

 

For further information, refer to the detailed PARP Inhibitors Unmet Needs, PARP Inhibitors Market Drivers, and Market Barriers, click here for PARP Inhibitors Ongoing Clinical Trial Analysis

 

Scope of the PARP Inhibitors Pipeline Report

 

  • Coverage- Global

 

  • PARP Inhibitors Companies- TESARO, AstraZeneca, Sun BioPharma, Eisai Co, BeiGene,  IMPACT Therapeutics, Ribon Therapeutics, Pfizer, Medivation Inc, AbbVie, Merck Sharp & Dohme LLC, Bristol-Myers Squibb, and others

 

  • PARP Inhibitors Pipeline Therapies- Talazoparib, Veliparib, carboplatin, Paclitaxel, Olaparib, Rucaparib, Nivolumab, Abiraterone, and others.

 

  • PARP Inhibitors Pipeline Segmentation: Product Type, Molecule Type, Route of Administration 

 

Dive deep into rich insights for drugs for PARP Inhibitors Market Drivers and PARP Inhibitors Market Barriers, click here @ PARP Inhibitors Unmet Needs and Analyst Views

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. PARP Inhibitors: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. PARP Inhibitors – DelveInsight’s Analytical Perspective
  7. In-depth Commercial Assessment
  8. PARP Inhibitors Collaboration Deals
  9. Late Stage Products (Phase III)
  10. Pamiparib: BeiGene
  11. Drug profiles in the detailed report…..
  12. Mid Stage Products (Phase II)
  13. Drug Name: Company Name
  14. Drug profiles in the detailed report…..
  15. Pre-clinical and Discovery Stage Products
  16. Drug Name: Company Name
  17. Drug profiles in the detailed report…..
  18. Inactive Products
  19. PARP Inhibitors Key Companies
  20. PARP Inhibitors Key Products
  21. PARP Inhibitors- Unmet Needs
  22. PARP Inhibitors- Market Drivers and Barriers
  23. PARP Inhibitors- Future Perspectives and Conclusion
  24. PARP Inhibitors Analyst Views
  25. PARP Inhibitors Key Companies
  26. Appendix

 

Got Queries? Find out the related information on PARP Inhibitors Mergers and acquisitions, PARP Inhibitors licensing activities @ PARP Inhibitors Emerging Drugs, and Recent Trends

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/